financetom
Business
financetom
/
Business
/
Goldshore Resources Changes Name to Gold X2
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Goldshore Resources Changes Name to Gold X2
Sep 2, 2025 11:32 AM

02:02 PM EDT, 09/02/2025 (MT Newswires) -- Goldshore Resources ( GSHRF ) up 13% on last look, on Tuesday said it changed its name to Gold X2 Mining and will trade under the AUXX.V.

The company's shares will begin trading under its new name and ticker symbol on the TSX Venture Exchange at market open on Sept. 4.

Goldshore shares were last seen up $0.05 to $0.425 on the TSX Venture Exchange.

Price: 0.43, Change: +0.05, Percent Change: +13.33

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRC Q4 Net Loss Narrows, Revenue Rises; Sets 2024 Revenue Outlook
BRC Q4 Net Loss Narrows, Revenue Rises; Sets 2024 Revenue Outlook
Mar 6, 2024
04:41 PM EST, 03/06/2024 (MT Newswires) -- BRC (BRCC) reported a Q4 net loss Wednesday of $0.07 per diluted share, narrowing from a loss of $0.09 a year earlier. Analysts polled by Capital IQ expected EPS of $0.01. Revenue for the quarter ended Dec. 31 was $119.7 million, up from $93.6 million a year earlier. Analysts surveyed by Capital IQ...
--Hess Keeps Quarterly Dividend at $0.4375 Per Share; Payable March 28 to Shareholders of Record on March 18
--Hess Keeps Quarterly Dividend at $0.4375 Per Share; Payable March 28 to Shareholders of Record on March 18
Mar 6, 2024
04:42 PM EST, 03/06/2024 (MT Newswires) -- Price: 143.49, Change: +0.47, Percent Change: +0.33 ...
Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy, Interim Data Shows
Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy, Interim Data Shows
Mar 6, 2024
ViiV Healthcare, majority owned by GSK Plc ( GSK ) , with Pfizer Inc ( PFE ) and Shionogi Limited as shareholders, revealed data from a planned interim analysis of the LATITUDE phase 3 trial. The data indicated that long-acting injectable antiretroviral treatment (ART) for HIV, Cabenuva (cabotegravir + rilpivirine), demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of...
Emergent BioSolutions Reports Q4 Results, Amends Credit Agreement
Emergent BioSolutions Reports Q4 Results, Amends Credit Agreement
Mar 6, 2024
Emergent Biosolutions Inc ( EBS ) shares are trading higher after the company amended its existing credit agreement and reported its fourth-quarter financial results. Here's a look at the details.  The Details: Emergent BioSolutions ( EBS ) reported quarterly losses of 77 cents per share, missing the analyst consensus estimate of losses of 19 cents per share. Quarterly sales came...
Copyright 2023-2026 - www.financetom.com All Rights Reserved